Introduction and Objectives

The present non-interventional study was performed to elucidate efficacy and tolerability of add-on therapy with Spasmex®30 in patients with an overactive bladder (OAB) and benign prostate syndrome (BPS) without obstruction who are insufficiently treated with an α-receptor blocker.

Introduction and Objectives

Biological tissues are widely used in urological surgeries to treat conditions like pelvic organ prolapse and stress urinary incontinence (SUI).

In Slovenia tension-free slings (tvt sling) to treat stress urinary incontinence caused by urethral hypermobility and intrinsic sphincter deficiency is used from the year 1998.

Introduction and Objective

Prostatic benign hyperplasia (PBH) is being recognized as a growing health problem worldwide. The incidence of Prostatic Benign Hyperplasia (PBH) has rapidly increased as life expectancy has risen and is now the most common disease in the aging male. Association between PBH and overactive bladder is not uncommon. Patients may present with urgency and urge-incontinence. Quantification of symptoms using the IPSS should be carried out during the initial evaluation. A safe and effective method to evaluate the deleterious effects of bladder outlet obstruction is not yet known. The thickness of the bladder wall measured sonographically has been advocated as a minimally invasive technique and has been widely discussed. In the present study, we analyzed the correlation among bladder wall thickness (BWT), post-void residual volume, prostate volume, IPSS and OAB-V8 symptom questionnaire.

Methods

This prospective observational study included patients who underwent transrectal ultrasound (TRUS) guided prostate biopsy under local anesthesia from January to July 2007. Only patients who had a pre-void bladder volume ranging from 150 to 300 ml in the transrectal ultrasound evaluation were eligible for the study. Several clinical, laboratory and ultrasound parameters were collected including PSA, pre and post-void bladder volume, BWT, prostate volume, IPSS and fluxometry.

Results

Data from 22 consecutive patients were available. The mean age was 66.5 years (+/- 7.02 years). Median PSA was 7.3 ng/mL (ranging from 3.2 to 55.7 ng/mL). Mean prostate volume (TRUS) was 49.32 (+/- 20.2) cm3. IPSS score ranged from 1 to 30 (median = 11.5). Mean BWT was 6.11 (+/- 1.44) mm. Bivariate analysis showed no statistical difference between stratified IPSS and BWT (p=0.55), and no statistical difference between stratified BWT and post-void residual volume (p=0.51). When comparing stratified IPSS (mild versus severe symptoms) and prostate volume, statistical significance was seen (Mann-Whitney, p<0.002). There was no statistical difference when comparing mean peak urinary flow to post-void residual volume (p=0.09).

Conclusions

In the present study, patients with higher IPSS scores had larger prostate volumes (ultrasound evaluation). However, there was not statistical difference between mean BWT and parameters as post-void residual volume, IPSS and OAB-V8 score. The clinical relevance of bladder wall thickness and its association with symptoms of overactive bladder or bladder outlet obstruction should be further studied.

Keywords

Prostate; Bladder obstruction; Ultrasonography; Urinary Incontinence

Objectives

The study was an open-label, randomized, parallel, three-treatment, dose-ranging pharmacokinetic study.